Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retèl; Sabine C. Linn; Wim H. van Harten

doi:10.1200/JCO.2014.59.8029

Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retèl, Sabine C. Linn, Wim H. van Harten

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

127 Downloads (Pure)

Abstract

In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.

Original language	English
Pages (from-to)	1626-1627
Journal	Journal of clinical oncology
Volume	33
Issue number	14
DOIs	https://doi.org/10.1200/JCO.2014.59.8029
Publication status	Published - 2015

Keywords

METIS-311885
IR-97319

Access to Document

10.1200/JCO.2014.59.8029

Retel2015molecularFinal published version, 61.6 KB

Cite this

@article{2b4e2750dfca47c3b70fad35246bb987,

title = "Molecular Profiling Is Rather Likely to Be Cost Effective",

abstract = "In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.",

keywords = "METIS-311885, IR-97319",

author = "Ret{\`e}l, {Valesca P.} and Linn, {Sabine C.} and {van Harten}, {Wim H.}",

year = "2015",

doi = "10.1200/JCO.2014.59.8029",

language = "English",

volume = "33",

pages = "1626--1627",

journal = "Journal of clinical oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "14",

}

TY - JOUR

T1 - Molecular Profiling Is Rather Likely to Be Cost Effective

AU - Retèl, Valesca P.

AU - Linn, Sabine C.

AU - van Harten, Wim H.

PY - 2015

Y1 - 2015

N2 - In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.

AB - In a recent report, Bonastre et al1 calculated the cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer and concluded that, under the present circumstances in France, the 70-gene signature (MammaPrint) is unlikely to be cost effective.

KW - METIS-311885

KW - IR-97319

U2 - 10.1200/JCO.2014.59.8029

DO - 10.1200/JCO.2014.59.8029

M3 - Article

VL - 33

SP - 1626

EP - 1627

JO - Journal of clinical oncology

JF - Journal of clinical oncology

SN - 0732-183X

IS - 14

ER -

Molecular Profiling Is Rather Likely to Be Cost Effective

Abstract

Keywords

Access to Document

Fingerprint

Cite this